APA

De Leeuw I., Vague P., Selam J., Skeie S., Lang H., Draeger E. & Elte J. W. F. (20050412). Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. : Diabetes, obesity & metabolism.

Chicago

De Leeuw I, Vague P, Selam J-L, Skeie S, Lang H, Draeger E and Elte J W F. 20050412. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. : Diabetes, obesity & metabolism.

Harvard

De Leeuw I., Vague P., Selam J., Skeie S., Lang H., Draeger E. and Elte J. W. F. (20050412). Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. : Diabetes, obesity & metabolism.

MLA

De Leeuw I, Vague P, Selam J-L, Skeie S, Lang H, Draeger E and Elte J W F. Insulin detemir used in basal-bolus therapy in people with type 1 diabetes is associated with a lower risk of nocturnal hypoglycaemia and less weight gain over 12 months in comparison to NPH insulin. : Diabetes, obesity & metabolism. 20050412.